Exploratory analysis of a phase 3 trial in 144 patients with ATTRv amyloidosis with polyneuropathy: eplontersen reduced serum TTR by 70.6% to 85.0% vs historical placebo across genetic variant groups, with neuropathy scores generally maintained and quality of life improved.
Secondary analysisn = 144 patients
Gillmore et al. Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO-TTRansform Trial